RNS Number: 0005N Intuitive Investments Group plc 17 January 2023

17 January 2023

Intuitive Investments Group plc

("IIG" or the "Company")

Result of Annual General Meeting and Directorate Change

Intuitive Investments Group plc (AIM: IIG), a closed-end investment company focussed on the life sciences sector, announces that at the Annual General Meeting held today, all resolutions were duly passed.

The results of the proxy voting are summarised in the table below:

Resolution	Votes For	Votes Against	Withheld
One	30,133,533	0	0
Two	30,133,533	0	0
Three	30,133,533	0	0
Four	30,133,533	0	0
Five	30,133,533	0	0
Six	30,133,533	0	0
Seven	30,133,533	0	0
Eight	30,133,533	0	0

IIG also announces that Dr Cormac Kilty, Independent Non-Executive Director, has informed the Board of his intentionto step down at the end of this month. Given the size of the Company, where the Board, further to Cormac's retirement, will consist of three independent non-executive and one executive director, a replacement is not being sought.

Julian Baines, Chairman of IIG, commented:

"On behalf of everyone at IIG, I would like to thank Cormac for his service at IIG as a non-executive director, particularly his hard work at the time of flotation and his subsequent input into the Company's investments. He will be sorely missed at Board meetings."

For further information, please contact:

Intuitive Investments Group plc
Julian Baines, Chairman

Robert Naylor, CEO

www.iigplc.com

Via Walbrook PR

SP Angel Corporate Finance LLP - Nominated Adviser

+44 (0) 20 3470 0470

Jeff Keating / David Hignell / Kasia Brzozowska

+44 (0) 20 3657 0050

Turner Pope Investments (TPI) Ltd - Broker Andrew Thacker / James Pope

Walbrook PR Limited - Media & Investor Relations

+44 (0)20 7933 8780 or <u>intuitive@walbrookpr.com</u> +44 (0) 7980 541 893 / +44 (0) 7502 558 258

About Intuitive Investments Group plc

Paul McManus / Sam Allen

Intuitive Investments Group plc is an investment company seeking to provide investors with exposure to a portfolio concentrating on fast growing and/or high potential Life Sciences businesses operating predominantly in the UK, continental Europe and the US, utilising the Board's experience and in particular that of the Chairman of the Investment Committee, David Evans, to seek to generate capital growth over the long term for shareholders

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact msc.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this

communication, and t	o share such analysis on a	n anonymised basis with c	others as part of our	commercial services.	For further info	ormation about how
RNS and the London	Stock Exchange use the pe	ersonal data you provide us	s, please see our <u>Pr</u>	ivacy Policy.		

END

RAGBBGDBXBBDGXR